Medidata Solutions (NASDAQ:MDSO) released its earnings results on Thursday. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.05, Bloomberg Earnings reports. The company had revenue of $149.20 million during the quarter, compared to analysts’ expectations of $146.73 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. Medidata Solutions’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same period last year, the business earned $0.31 EPS.
Shares of NASDAQ MDSO opened at $73.46 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.19. Medidata Solutions has a 12 month low of $59.60 and a 12 month high of $85.92. The company has a market cap of $4,131.52, a price-to-earnings ratio of 80.17, a price-to-earnings-growth ratio of 3.66 and a beta of 1.53.
In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $67.47, for a total transaction of $134,940.00. Following the completion of the sale, the chief financial officer now directly owns 82,775 shares in the company, valued at approximately $5,584,829.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Tarek Sherif sold 26,836 shares of Medidata Solutions stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,836 shares of company stock valued at $2,362,769. Company insiders own 5.80% of the company’s stock.
A number of analysts recently commented on MDSO shares. TheStreet upgraded shares of Medidata Solutions from a “c+” rating to a “b-” rating in a research note on Monday, March 12th. Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a research note on Wednesday, February 14th. Needham & Company LLC lowered their target price on shares of Medidata Solutions to $75.00 and set a “buy” rating for the company in a research note on Friday, February 9th. ValuEngine upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Finally, Royal Bank of Canada set a $82.00 target price on shares of Medidata Solutions and gave the stock a “hold” rating in a research note on Thursday, February 8th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Medidata Solutions presently has a consensus rating of “Buy” and a consensus target price of $82.36.
TRADEMARK VIOLATION NOTICE: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://stocknewstimes.com/2018/04/20/medidata-solutions-mdso-releases-earnings-results-beats-estimates-by-0-05-eps.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.